Last reviewed · How we verify
quetiapine (Seroquel) XR
Quetiapine is an atypical antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood.
Quetiapine is an atypical antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Major depressive disorder (adjunctive treatment).
At a glance
| Generic name | quetiapine (Seroquel) XR |
|---|---|
| Also known as | Seroquel XR, Seroquel, Seroquel XR tablet, Seroquel_XR (Quetiapine Fumarate XR) |
| Sponsor | Dr. D McIntosh & Dr. K Kjernisted Clinical Research Inc. |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | FDA-approved |
Mechanism of action
Quetiapine antagonizes dopamine D1 and D2 receptors as well as serotonin 5-HT1A and 5-HT2A receptors. The extended-release formulation provides sustained drug levels, allowing once-daily dosing. This receptor antagonism reduces hyperactivity in mesolimbic and mesocortical dopamine pathways implicated in psychosis and mood dysregulation.
Approved indications
- Schizophrenia
- Bipolar I disorder (acute mania and maintenance)
- Major depressive disorder (adjunctive treatment)
- Generalized anxiety disorder
Common side effects
- Somnolence/sedation
- Dry mouth
- Dizziness
- Weight gain
- Headache
- Orthostatic hypotension
- Tachycardia
Key clinical trials
- A Study of the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia. (PHASE3)
- Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis (PHASE4)
- Quetiapine for Bipolar Disorder and Alcohol Dependence (PHASE4)
- Study to Evaluate the Effect and Safety of Quetiapine Extended Release (XR) (FK949E) in Major Depressive Disorder (PHASE2)
- Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
- Comparison of Antidepressant Augmentation With Amantadine vs Pramipexole vs Quetiapine in Treatment Resistant Depression (PHASE4)
- Pioglitazone and Quetiapine XR Pharmacogenetic Study
- Efficacy of Hydroxyzine for Patients With Panic Disorder (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: